Related Experiment Videos
Visual pathway glioma in children treated with chemotherapy
Philippe Demaerel1, Nele de Ruyter, Ingele Casteels
1Department of Radiology, University Hospitals, Leuven, Belgium. philippe.demaerel@uz.kuleuven.ac.be
Summary
Chemotherapy effectively treats visual pathway gliomas in young children. Patients with neurofibromatosis type 1 showed no disease progression, suggesting a potential protective effect.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Ophthalmology
Background:
- Visual pathway gliomas predominantly affect young children.
- Chemotherapy is increasingly favored over radiotherapy and surgery due to associated complications.
- Neurofibromatosis type 1 is a common comorbidity.
Purpose of the Study:
- To evaluate the efficacy of vincristine and carboplatin chemotherapy in pediatric visual pathway gliomas.
- To assess the role of magnetic resonance imaging (MRI) in monitoring treatment response.
- To investigate the impact of neurofibromatosis type 1 on disease progression.
Main Methods:
- Nine children (6 months–9 years) received vincristine and carboplatin per the SIOP low-grade glioma 1996 protocol.
- Five patients had neurofibromatosis type 1.
- Treatment response was monitored using MRI and ophthalmological assessments.
Main Results:
- All patients (100%) showed a positive treatment response.
- Three patients experienced disease progression 8–12 months after treatment cessation.
- Patients with neurofibromatosis type 1 did not develop progressive disease.
Conclusions:
- Chemotherapy is an effective treatment for pediatric visual pathway gliomas.
- MRI, with a standardized protocol, is crucial for monitoring tumor response.
- Neurofibromatosis type 1 may be associated with a better prognosis in these patients.